Effect of AT1 receptor blockade on hepatic redox status in SHR: Possible relevance for endothelial function?

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 285, Issue 3 54-3, 2003, Pages

  Cediel, Eva ^c   Sanz Rosa, David ^c   Oubiña, M Pilar ^c   De las Heras, Natalia ^c   González Pacheco, Francisco R ^b   Vegazo, Onofre ^a   Jiménez, Javier ^a   Cachofeiro, Victoria ^c   Lahera, Vicente ^c,d  

^a Astra Zeneca   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c SCHOOL OF MEDICINE   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Angiotensin II; Angiotensin II receptor antagonists; Antioxidant defense; Hypertension; Nitric oxide; Oxidative stress

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; COMPLEMENTARY DNA; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; MALONALDEHYDE; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; CARRIER PROTEIN; CYBA PROTEIN, HUMAN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE DISULFIDE; NITRIC OXIDE; NOS3 PROTEIN, RAT; PHOSPHOPROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTERY MEDIA; ARTERY MUSCLE; ARTICLE; CONTROLLED STUDY; HYPERTENSION; LIVER; LIVER HOMOGENATE; NONHUMAN; NORTHERN BLOTTING; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; RAT STRAIN; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; ANIMAL; AORTA; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM; WISTAR KYOTO RAT;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; BENZIMIDAZOLES; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HYPERTENSION; LIVER; MALONDIALDEHYDE; MEMBRANE TRANSPORT PROTEINS; NADPH DEHYDROGENASE; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHOSPHOPROTEINS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0141497085     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00643.2002     Document Type: Article

References (51)

1. Abe JL and Berk BC. Reactive oxygen species as mediators of signal transduction in cardiovascular disease. Cardiovasc Med 8: 59-64, 1998.
2. Alexander MY, Brosnan MJ, Hamilton CA, Downie P, Devlin AM, Dowell F, Martin W, Prentice HM, O'Brien T, and Dominiczak AF. Gene transfer of endothelial nitric oxide synthase improves nitric-oxide-dependent endothelial function in a hypertensive rat model. Cardiovasc Res 43: 798-807, 1999.
3. Bennai F, Morsing P, Paliege A, Ketteler M, Mayer B, Tapp R, and Bachmann S. Normalizing the expression of nitric oxide synthase by low-dose AT1 receptor antagonism parallels improved vascular morphology in hypertensive ras. J Am Soc Nephrol 10, Suppl 11: S104-S115, 1999.
4. Brosnan MJ, Hamilton CA, Graham D, Lygate CA, Jardine E, and Dominiczak AF. Irbesartan lowers superoxide levels and increase nitric oxide bioavailability in blood vessels from spontaneously hypertensive rats. J Hypertens 20: 281-286, 2002.
5. Cachofeiro V, Maeso R, Rodrigo E, Navarro J, Ruilope LM, and Lahera V. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension 26: 236-243, 1995.
6. Carbonell LF, Nadal JA, Llanos MC, Hernández I, Nava E, and Diaz J. Depletion of liver glutathione potentiates the oxidative stress and decreases nitric oxide synthesis in rat endotoxin shock model. Crit Care Med 28: 2002-2006, 2000.
7. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 15: 532-537, 1993.
8. Dayal S, Brown KL, Weydert CJ, Oberley LW, Arning E, Bottiglieri T, Faraci FM, and Lentz SR. Deficiency of glutathione peroxidase-1 sensitizes hyperhomocysteinemic mice to endothelial dysfunction. Arterioscler Thromb Vasc Biol 22: 1996-2002, 2002.
9. De las Heras N, Aragoncillo P, Maeso R, Vázquez-Pérez S, Navarro-Cid J, De Gasparo M, Mann J, Ruilope LM, Cachofeiro V, and Lahera V. AT1 receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension 34: 969-975, 1999.
10. Demling R, Lalonde C, Picard L, and Blanchard J. Changes in lung and systemic oxidant and antioxidant activity after smoke inhalation. Shock 1: 101-107, 1994.
11. Fava D, Cassone-Faldetta M, Laurenti O, De Luca O, Ghiselli A, and De Mattia G. Gliclazide improves antioxidant status end nitric oxide-mediated vasodilation in type 2 diabetes. Diabet Med 19: 752-757, 2002.
12. Ghiadoni L, Virdis A, Magagna A, Taddei S, and Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 35: 501-506, 2000.
13. Gibbons GH. Endothelial function as a determinant of vascular function and structure: A new therapeutic target. Am J Cardiol 79: 3-8, 1997.
14. Gonzalez Bosc LV, Kurnjek ML, Muller A, Terragno NA, and Basso N. Effect of chronic angiotensin II inhibition on nitric oxide synthase in the normal rat during aging. J Hypertens 19: 1403-1409, 2001.
15. Halliwell B and Guteridge JM. The definition and measurement of antioxidants in biological systems. Free Radic Biol Med 18: 125-126, 1995.
16. Heistad DD, Armstrong ML, Baumbach GL, and Faraci FM. Sick vessel syndrome. Recovery of atherosclerotic and hypertensive vessels. Hypertension 26: 509-513, 1995.
17. Higashi T, Kobayashi N, Hara K, Sjirataki H, and Matsuoka H. Effects of angiotensin II type 1 receptor antagonist on nitric oxide synthase expression and myocardial remodelling in Goldblatt hypertensive rats. J Cardiovasc Pharmacol 35: 564-571, 2000.
18. Kaplowitz N, Aw TY, and Ootkens M. The regulation of hepatic glutathione. Annu Rev Pharmacol Toxicol 25: 715-744, 1985.
19. Kidd PM. Glutathione: systemic protectant against oxidative and free radical damage. Alt Med Rev 2: 155-176, 1997.
20. Kobayashi N, Mori Y, Nakano S, Tsubokou Y, Kobayashi T, Shirataki H, and Matsuoka H. TCV-116 stimulates eNOS and caveolin-1 expression and improves coronary microvascular remodelling in normotensive and angiotensin II-induced hypertensive rats. Atherosclerosis 158: 359-368, 2001.
21. Kobayashi N, Nishikimi T, Horinaka S, Ishimitsu T, and Matsuoka H. Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt-sensitive rats. Atherosclerosis 156: 255-265, 2001.
22. Kugiyama K, Ohgushi M, Motoyama T, Hirashima O, Soejima H, Misumi K, Yoshimura M, Ogawa H, Sugiyama S, and Yasue H. Intracoronary infusion of reduced glutathione improves endothelial vasomotor response to acetylcholine in human coronary circulation. Circulation 97: 2299-2301, 1998.
23. Lou YK, Wen C, Li M, Adams DJ, Wang M, Yang F, Morris BJ, and Whithworth JA. Decreased renal expression of nitric oxide synthase isoforms in adrenocorticotropin-induced and corticosterone-induced hypertension. Hypertension 37: 1164-1170, 2001.
24. Lüscher TF and Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 8: 344-348, 1986.
25. Maeso R, Rodrigo E, Muñoz-García R, Navarro-Cid J, Ruilope LM, Cachofeiro V, and Lahera V. Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. J Hypertens 16: 665-672, 1998.
26. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, Kamitani S, Harada M, Ishikawa M, Kuwahara K, Ogawa E, Hamanaka I, Takahahi N, Kaneshige T, Teraoka H, Akamizu T, Azuma N, Yoshimasa T, Itoh H, Masuda I, Yasue H, and Nakao K. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 32: 3-8, 1998.
27. Mombouli JV and Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 31: 61-74, 1999.
28. Moreno C, Lopez A, Llinas MT, Rodriguez F, Lopez-Farré Nava A, and Salazar FJ. Changes in NOS activity and protein expression during acute and prolonged angiotensin II administration. Am J Physiol Regul Integr Comp Physiol 282: R31-R37, 2002.
29. Münzel T, Just H, and Harrison DG. The physiology and pathophysiology of the nitric oxide/superoxide system. In: Vascular Endothelium: Physiology, Pathology, and Therapeutic Options, edited by Born GVR and Schwartz CJ. Stuttgart, Germany: Schattauer, 1997, p. 205-220.
30. Munzel T, Hink U, Heitzer T, and Meinertz T. Role for NADPH/NADH oxidase in the modulation of vascular tone. Ann NY Acad Sci 874: 386-400, 1999.
31. Nakazono K, Watanabe N, Matsuno K, Sasaki J, and Sato T. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 88: 10045-10048, 1991.
32. Olson SC, Dowds TA, Pino PA, Barry MT, and Burke-Wollin T. Ang II stimulates endothelial nitric oxide synthase expression in bovine pulmonary artery endothelium. Am J Physiol Lung Cell Mol Physiol 273: L315-L321, 1997.
33. Owens GK. Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension 9: 178-187, 1987.
34. Panza JA, Garcia CE, Kilcoy-no CM, Quyyumi AA, and Cannon RO. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 91: 1732-1738, 1995.
35. Pinzani M and Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 21: 397-416, 2001.
36. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, and Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest 97: 1916-1923, 1996.
37. Rizzoni D, Porteri E, Bettoni G, Piccoli A, Castellano M, Muiesan ML, Pasini G, Guelfi D, and Agabiti-Rosei E. Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol 32: 798-806, 1998.
38. Rodrigo E, Maeso R, Muñoz-García R, Navarro-Cid J, Ruilope LM, Cachofeiro V, and Lahera V. Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril. J Hypertens 15: 613-618, 1997.
39. Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol 28: 803-812, 1996.
40. Safar ME, London GM, Asmar R, and Frohlich ED. Recent advances on large arteries in hypertension. Hypertension 32: 156-161, 1998.
41. Schiffrin EL and Deng LY. Comparison of effects of angiotensin I converting enzyme inhibition and beta blockade for two years on function small arteries from hypertensive patients. Hypertension 25: 699-703, 1995.
42. Schiffrin EL, Park JB, Intengan HD, and Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 101: 1653-1659, 2000.
43. Suzuki M, Fukuhara K, Unno M, Htwe T, Takeuchi H, Kakita T, and Matsuno S. Correlation between plasma and hepatic phosphatidylcholine hydroperoxide, energy charge, and total glutathione content in ischemia reperfusion injury of rat liver. Hepatogastroenterology 47: 1082-1089, 2000.
44. Thybo NK, Stwephens N, Cooper A, Aalkjaer C, Heagerty AM, and Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 25: 474-481, 1995.
45. Tsukahara H, Hiraoka M, Kobata R, Hata I, Ahshima Y, Jiang MZ, Moiri E, and Mayumi M. Increased oxidative stress in rats with chronic nitric oxide depletion: measurement of urinary 8-hydroxy-2′-deoxyguanosine excretion. Redox Rep 5: 23-28, 2000.
46. Vázquez-Pérez S, Navarro-Cid J, de las Heras N, Cediel E, Sanz-Rosa Ruilope LM, Cachofeiro V, and Lahera V. Relevance of endothelium-derived hyperpolarizing factor in the effects of hypertension on rat coronary relaxations. J Hypertens 19: 539-545, 2001.
47. Wickman A, Andersson JL, Jia J, Hedin L, and Bergstrom G. Endothelial nitric oxide synthase protein is reduced in the renal medulla of two-kidney, one clip hypertensive rats. J Hypertens 19: 1665-1673, 2001.
48. Yoshiyama M, Takeuchi K, Omura T, Kim S, Yamagishi H, Toda I, Teragaki M, Akioka K, Iwao H, and Yoshikawa J. Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. Hypertension 33: 961-968, 1999.
49. Yu BP. Cellular defenses against damage from reactive oxygen species. Physiol Rev 74: 139-161, 1991.
50. Zalba G, Beaumont FJ, San Jose G, Fortuño A, Fortuño MA, and Diez J. Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction? Nephrol Dial Transplant 16, Suppl 1: 2-5, 2001.
51. Zalba G, San José G, Moreno MU, Fortuño MA, Fortuño A, Beaumont FJ, and Díez J. Oxidative stress in arterial hypertension. Hypertension 38: 1395-1401, 2001.